Hawthorne, NY-based Acorda Therapeutics (NASDAQ: ACOR) held its first R&D day for Wall Street analysts in six years today, and when CEO Ron was asked 'why now?' his answer was simple. The company had been focused all those years on getting its …
<a href="http://www.google.com/url?sa=X&q=http://news.google.com/news/story?ncl=http://www.xconomy.com/new-york/2012/04/17/five-questions-acorda-ceo-ron--on-the-future-of-neurology-rd/&hl=en&geo=us&ct=ga&cad=CAcQARgAIAAoBjAAOABAopS3_ARIAlAAWABiBWVuLVVT&cd=2Em9GyoVDok&usg=AFQjCNGtRW8S7PTthzM18f06KLxg-U6_VQ” title=”http://news.google.com/news/story?ncl=http://www.xconomy.com/new-york/2012/04/17/five-questions-acorda-ceo-ron--on-the-future-of-neurology-rd/&hl=en&geo=us”>See all stories on this topic »